The Hormel Institute Scientists Receive Grant to Continue Studying Deadly Type of Pediatric Brain Cancer
The research could lead to a new treatment for the disease, which now has a survival rate of less than one year
Austin Minn – August 26, 2021 – The Hormel Institute’s Dr. Edward “Ted” Hinchcliffe, Professor of Cell Biology and head of the Cellular Dynamics lab, has been awarded a U.S Department of Defense Pediatric Brain Cancer Research Grant. The $800,000 grant starts on September 1, 2021 and runs until 2024.
Dr. Hinchcliffe is collaborating with Dr. James Robinson, Assistant Professor and head of the Cell Signaling & Tumorigenesis lab at The Hormel Institute, to explore a potential therapy for diffuse midline gliomas, an extremely aggressive type of pediatric brain tumor. There is not currently any treatment for this type of cancer and the survival rate is less than one year from diagnosis.
“We are using therapeutic agents that stimulate the innate immune system to attack the tumor cells. The innate immune system is normally triggered in these tumors by mis-segregation of chromosomes during cell division, but can become ‘silenced’. Our goal is to ‘wake it up’,” said Dr. Hinchcliffe. “We are also testing a second therapeutic agent to try and increase chromosome mis-segregation in the tumors to see if this can boost the effect.”
This is Dr. Hinchcliffe’s third grant in a row from the Department of Defense, dating back to 2013. The preliminary data used to obtain this funding was generated with the support from the University of Minnesota – Mayo Clinic Partnership Grant Dr. Hinchcliffe received in 2020.